LINEZOLID
Author:
- 1 January 2001
- journal article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 55 (1) , 59-63
Abstract
SUMMARY: Multiple antibiotic resistance is increasing worldwide in Gram‐positive bacteria, especially in hospitals. Problem organisms include multiply resistant strains of pneumococci,Staphylococcus aureusand enterococci; for many of these the glycopeptide vancomycin has become the treatment of last resort. This situation has been made worse by the emergence of vancomycin‐resistant enterococci and vancomycin‐intermediateS. aureus.Fortunately, several compounds active against resistant Gram‐positive bacteria are in active development. One of these is linezolid, the first of the oxazolidinones, a new class of antibacterial. Linezolid is a synthetic agent which is active against all the clinically important Gram‐positive bacteria, including multiply resistant strains. It has good pharmacokinetics, with equal bioavailability by both oral and intravenous routes and no need for dose adjustment in patients with renal impairment. The drug has a good safety profile and clinical trials have given excellent results in a variety of skin and soft tissue, respiratory and bloodstream infections. Linezolid is a promising drug, which, together with prudent antibiotic use and the prevention and control of hospital infection, will help in the battle against multiply antibiotic resistant Gram‐positive bacteria.Keywords
This publication has 30 references indexed in Scilit:
- Frequency of Occurrence and Antimicrobial Susceptibility of Bacterial Pathogens Associated with Skin and Soft Tissue Infections During 1997 from an International Surveillance ProgrammeEuropean Journal of Clinical Microbiology & Infectious Diseases, 1999
- Comparative Activity of 27 Antimicrobial Compounds Against 698 Streptococcus pneumoniae Isolates Originating from 20 European University HospitalsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1999
- Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY antimicrobial surveillance programDiagnostic Microbiology and Infectious Disease, 1999
- Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989–95The Lancet, 1997
- Antimicrobial Resistance in Isolates from Inpatients and Outpatients in the United States: Increasing Importance of the Intensive Care UnitClinical Infectious Diseases, 1997
- Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial InfectionsJournal of Medicinal Chemistry, 1996
- The Crisis in Antibiotic ResistanceScience, 1992
- Epidemiology of Drug Resistance: Implications for a Post—Antimicrobial EraScience, 1992
- Antimicrobial Resistance in Streptococcus pneumoniae: An OverviewClinical Infectious Diseases, 1992
- Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721Antimicrobial Agents and Chemotherapy, 1987